CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.56B, above the global median of $1.2B
- PositionReturn on equity is 35.7%, higher than 95% of its Biotechnology peers (median -22.4%)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
3.56BUSDvs all stocks (USD)
Trailing P/E
9.27xvs Biotechnology peers
Revenue (TTM)
1.14BUSDvs all stocks (USD)
Profit Margin
33.42%vs Biotechnology peers
Beta
0.8570xvs all stocks
52-Week Change
-3.00%vs all stocks
Market Capitalization
3.56BUSDvs all stocks (USD)
Enterprise Value
2.68BUSDvs all stocks (USD)
Trailing P/E
9.27xvs Biotechnology peers
Forward P/E
23.24xvs Biotechnology peers
PEG Ratio
0.7419xvs Biotechnology peers
Price to Sales (TTM)
3.11xvs Biotechnology peers
Price to Book (MRQ)
2.72xvs Biotechnology peers
Enterprise to Revenue
2.35xvs Biotechnology peers
Enterprise to EBITDA
27.25xvs Biotechnology peers
Gross Margin
90.81%vs Biotechnology peers
Profit Margin
33.42%vs Biotechnology peers
Operating Margin
12.29%vs Biotechnology peers
Return on Assets (TTM)
3.64%vs Biotechnology peers
Return on Equity (TTM)
35.74%vs Biotechnology peers
Revenue (TTM)
1.14BUSDvs all stocks (USD)
Revenue per Share (TTM)
6.69USDUpdated Sep 26, 2026Quarterly Revenue Growth
16.40%vs Biotechnology peers
Gross Profit (TTM)
706.66MUSDvs all stocks (USD)
EBITDA (TTM)
116.57MUSDvs all stocks (USD)
Net Income (TTM)
380.48MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.10%vs Biotechnology peers
Operating Cash Flow (TTM)
160.32MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
68.65MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.07BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
89.00MUSDFY2025 · Dec 31, 2025Gross Profit
982.51MUSDFY2025 · Dec 31, 2025Operating Income
104.81MUSDvs all stocks (USD)
Pre-tax Income
138.90MUSDFY2025 · Dec 31, 2025Income Tax Expense
-252.10MUSDFY2025 · Dec 31, 2025Net Income
391.00MUSDFY2025 · Dec 31, 2025EBIT
104.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
116.57MUSDFY2025 · Dec 31, 2025Research & Development
328.80MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
548.89MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
31.72MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.32USDFY2025 · Dec 31, 2025EPS (Diluted)
2.30USDFY2025 · Dec 31, 2025Basic Shares Outstanding
168.36MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
168.36MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
391.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
138.37MUSDFY2025 · Dec 31, 2025Free Cash Flow
133.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
185.54MUSDFY2025 · Dec 31, 2025Income Tax Paid
25.17MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
391.00MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.76MUSDFY2025 · Dec 31, 2025Stock-based Compensation
52.13MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-249.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-43.54MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-5.29MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.82MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.69MUSDFY2025 · Dec 31, 2025Net Acquisitions
-98.84MUSDFY2025 · Dec 31, 2025Purchase of Investments
-692.57MUSDFY2025 · Dec 31, 2025Sale of Investments
493.53MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-302.56MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
49.88MUSDFY2025 · Dec 31, 2025Shares Outstanding
172.13MSharesUpdated Sep 26, 2026Float Shares
128.35MSharesUpdated Sep 26, 2026Shares Short
9.67MSharesUpdated Sep 26, 2026Short Ratio
6.94daysvs all stocks
Short % of Shares Outstanding
8.87%vs all stocks
% Held by Insiders
0.33%vs all stocks
% Held by Institutions
99.78%vs all stocks
Total Cash (MRQ)
956.47MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.55USDUpdated Sep 26, 2026Total Debt (MRQ)
73.85MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0565xvs Biotechnology peers
Current Ratio (MRQ)
3.39xvs Biotechnology peers
Book Value per Share (MRQ)
7.59USDUpdated Sep 26, 2026Total Assets
1.56BUSDvs all stocks (USD)
Total Current Assets
1.06BUSDFY2025 · Dec 31, 2025Total Liabilities
336.81MUSDFY2025 · Dec 31, 2025Total Non-current Assets
502.08MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
59.69MUSDFY2025 · Dec 31, 2025Total Current Liabilities
277.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
177.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
641.99MUSDFY2025 · Dec 31, 2025Accounts Receivable
121.46MUSDFY2025 · Dec 31, 2025Inventory
34.67MUSDFY2025 · Dec 31, 2025Accounts Payable
10.90MUSDFY2025 · Dec 31, 2025Short-term Debt
11.63MUSDFY2025 · Dec 31, 2025Long-term Debt
40.55MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
19.14MUSDFY2025 · Dec 31, 2025Common Stock (Book)
16.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.81BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.23BUSDvs all stocks (USD)
52-Week Low
19.69USDUpdated Sep 26, 202652-Week High
30.96USDUpdated Sep 26, 202652-Week Change
-3.00%vs all stocks
Beta
0.8570xvs all stocks
50-Day MA
27.45USDUpdated Sep 26, 2026200-Day MA
24.57USDUpdated Sep 26, 2026Avg 10-Day Volume
2.52MSharesUpdated Sep 26, 2026Avg 30-Day Volume
1.76MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
2.23USDUpdated Sep 26, 2026Other Income / Expense
2.37MUSDFY2025 · Dec 31, 20255 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 35.7%, higher than 95% of its Biotechnology peers (median -22.4%)Significant
Return on equity: 0.36Industry median: -0.22Industry P95: 0.23Peers compared: 184
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 380,484,000Operating Cash Flow (USD, TTM): 160,319,008
Financial Health
Altman Z-Score 6.23: safe zoneNotable
Altman Z-Score: 6.23
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.56B, above the global median of $1.2BNotable
Market cap (USD): 3,563,278,112Global Median: 1,201,862,193
Revenue is $1.14B, above the global median of $558.46MNotable
Revenue (USD): 1,138,643,968Global Median: 558,459,881.051
Levered free cash flow is $68.65M, above the global median of $18.92MNotable
Levered free cash flow (USD): 68,647,000Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Organon & Co.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Grand Pharmaceutical and Healthcare Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
MiMedx Group, Inc.
4 interpretationsRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Sk Biopharmaceuticals Co., Ltd.
4 interpretationsMinimal Tax and Interest DragRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Shanghai Henlius Biotech, Inc.
4 interpretationsMinimal Tax and Interest DragRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated